Novartis Q4 Results slide image

Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References LeqvioⓇ adoption continues to expand across regions Sales evolution USD m, % cc US Ex-US FY USD 355m +217% +190% 123 GROWTH US: Steady growth, ahead of advanced lipid lowering market¹ Adoption • 3,500 facilities have ordered Leqvio® (+13% vs. Q3) ~55% of business is from in-office buy & bill Continued execution on growth enablers • Depth is increasing in key accounts • Buy & bill is fastest growing acquisition channel Improved HCP targeting driving increase in breadth and depth Ex-US: Rollout continues 29 countries with public reimbursement • 39 countries have private (commercial) coverage LEQVIO® (inclisiran) • 54 42 17 69 25 Q4 2022 Q4 2023 - HCP healthcare professional. 1. Includes PCSK9 mAbs and bempedoic acid. □ NOVARTIS | Reimagining Medicine. • Solid early uptake in China self-pay market Outcomes trials . On track for readout 2026+ Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report. Novartis Q4 Results | January 31, 2024 14
View entire presentation